Skip to main content

Advertisement

Table 2 Clinical and therapeutic characteristics

From: Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use

Variables Total number of patients (n = 61) Cannabis users (n = 9) Cannabis non-users (n = 52) p
Psychiatric diagnosis
 Schizophrenia 20 (32.9%) 5 (55.5%) 15 (28.8%)  
 Schizophreniform disorder 26 (42.6%) 1 (11.1%) 25 (48.1%)  
 Brief psychotic disorder 10 (16.4%) 1 (11.1%) 9 (17.2%) 0.10
 Cannabis-induced psychosis 3 (4.9%) 2 (22.2%) 1 (1.9%)  
 Delusional psychosis 1 (1.6%) 0 (0%) 1 (1.9%)  
 Psychotic disorder not otherwise specified 1 (1.6%) 0 (0%) 1 (1.9%)  
 PANSS total score 99.5 ± 20.6 101.6 ± 20.5 99.1 ± 20.8 0.65
 PANSS positive score 25.1 ± 6 27 ± 6.3 24.8 ± 6 0.43
 PANSS negative score 24.3 ± 9.3 25.7 ± 9.8 24 ± 9.3 0.56
 GAF score 32.4 ± 8 30 ± 5.6 33.5 ± 8.3 0.28
 Duration of untreated psychosis (weeks) 39.6 ± 63.7 28.6 ± 35.2 41.5 ± 87.4 0.45
Antipsychotic treatment
 First-generationantipsychotic 25(41%) 4 (44.4%) 21 (40.4%)  
 Second-generationantipsychotic 19 (31.1%) 2 (22.2%) 17 (32.7%) 0.84
 Co-treatment of first- and second-generation antipsychotics 17 (27.8%) 3 (33.3%) 14 (26.9%)  
 Chlorpromazine equivalent 619.8 ± 419.8 mg 914.0 ± 629.8 mg 568.8 ± 356.6 mg 0.16
 Simpson Angus scale score 3.8 ± 3.2 4.3 ± 2.6 3.7 ± 3. 0.37
 Duration of hospitalization (days) 29.1 ± 16.6 43.3 ± 15.5 26.7 ± 15.6 0.005
  1. GAF Global Assessment of Functioning, PANSS Positive and Negative Symptom Scale